Commercialization in the European Market Begins in Full

Johnson & Johnson (JNJ)'s treatment for generalized myasthenia gravis (gMG), Imaavy (active ingredient: nipocalimab), has received final marketing authorization from the European Commission (EC). This approval followed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) in September 2025 and was officially announced on November 28. As a result, Imaavy can now be prescribed as an add-on therapy for adult and pediatric patients aged 12 years and older who are positive for acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) autoantibodies. This marks a significant step in expanding JNJ's autoimmune portfolio into key global markets.

Efficacy and Safety Proven Through Phase 3 Clinical Data

The approval was based on data from the global Phase 3 VIVACITY-MG3 trial, which demonstrated the clinical utility of Imaavy. Clinical results showed a statistically significant improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to the placebo group when used in combination with standard therapy. Specifically, the Imaavy-treated group showed a least squares mean (LS mean) difference of -1.45 (p=0.002), demonstrating clinical superiority. Additionally, the safety profile over the 24-week treatment period was comparable to the placebo group, confirming its favorable tolerability.

Innovative Mechanism Targeting Pathogenic Autoantibodies

Imaavy is a monoclonal antibody that targets the neonatal Fc receptor (FcRn). It works by blocking the circulation of pathogenic immunoglobulin G (IgG) autoantibodies that interfere with nerve transmission and cause muscle weakness, thereby facilitating their rapid clearance from the body. Unlike broad-spectrum immunosuppressive agents currently used as standard treatments, Imaavy selectively reduces autoantibodies, significantly lowering the risk of opportunistic infections and adverse effects. This differentiated mechanism is expected to provide a compelling alternative for patients who have shown limited response to existing therapies.

Market Share Competition with a Leading $4 Billion Player

The global market for generalized myasthenia gravis in the 7 Major Markets (7MM) is estimated at approximately $5.9 to $6 billion in 2025 and is projected to exceed $15.6 billion by 2036. Currently, argenx (ARGX)'s Vyvgart leads the market with global net sales of $4.2 billion in 2025. With the addition of UCB's Rystiggo and now Imaavy, a three-way competition among FcRn inhibitors is anticipated. Johnson & Johnson aims to demonstrate the value of its robust sales infrastructure and the pipeline strengthened by its $6.5 billion acquisition of Momenta Pharmaceuticals in 2020.

Intensifying Pricing Negotiations in Europe for Revenue Diversification

While approval for entry into the European market has been secured, achieving real revenue contribution will depend on urgent negotiations for pricing and reimbursement in individual countries. Overcoming the rigorous cost-effectiveness evaluations in each nation is essential for establishing a foothold in the prescription market. Johnson & Johnson has already secured U.S. FDA approval on April 30, 2025, and now with this European approval, it is completing its global two-track commercialization strategy. The company's ability to rapidly secure insurance coverage in key member states will be a key factor in driving quarterly revenue growth in the near term.